Corticosteroid use in the treatment of neuromuscular disorders: Empirical and evidence-based data

Muscle and Nerve

Volumn 30, Issue 1, 2004, Pages 20-37

  Bromberg, Mark B ^a   Carter, Orly ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Corticosteroids; Dermatomyositis; Duchenne dystrophy; Myasthenia gravis; Neuromuscular disorders; Polymyositis

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; DEFLAZACORT; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; TETRACOSACTIDE; VITAMIN D;

ADRENAL SUPPRESSION; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; ASEPTIC NECROSIS; BEHAVIOR DISORDER; CATARACT; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DEMYELINATING DISEASE; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; EUPHORIA; EVIDENCE BASED MEDICINE; FEVER; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GLAUCOMA; GLUCOSURIA; HIRSUTISM; HUMAN; HYPERTENSION; INFECTION; LETHARGY; LIVER TOXICITY; LONG TERM CARE; MANIA; MENTAL DISEASE; MENTAL INSTABILITY; META ANALYSIS; MOOD DISORDER; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOPATHY; NAUSEA; NEUROMUSCULAR DISEASE; OSTEOPENIA; OSTEOPOROSIS; PEPTIC ULCER; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; STOMACH ULCER; TUBERCULOSIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ADRENAL CORTEX HORMONES; EVIDENCE-BASED MEDICINE; HUMANS; NEUROMUSCULAR DISEASES;

EID: 3042730547     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20075     Document Type: Review

References (179)

1. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
2. Adachi J, Bensen W, Bianchi F, Cividino A, Pillersdorf S, Sebaldt R, Tugwell P, Gordon M, Steele M, Wevver C, Goldsmith C. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
3. Amatruda T, Hurst M, D'Esopo N. Certain endocrine and metabolic facets of the steroid withdrawal syndrome. J Clin Endocrinol Metab 1965;25:1207-1217.
4. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-1801.
5. Anderson J. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994;330:1560-1564.
6. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F. Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther 1978;23:47-53.
7. Angelini C, Pegoraro E, Turella E, Intino M, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-391.
8. Arner P, Gunnarsson R, Blomdahl S, Groth C-G. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983;6:23-25.
9. Arsura E, Brunner N, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985;42:1149-1153.
10. Ashworth B, Smyth G. Relapsing motor polyneuropathy. Acta Neurol Scand 1969;45:342-350.
11. Askari A, Vignos P, Moskowitz R. Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-492.
12. Austin J. Recurrent polyneuropathies and their corticosteroid treatment. Brain 1958;81:157-195.
13. Axelrod L. Glucocorticoid therapy. Medicine 1976;55:39-65.
14. Barohn R, Kissel J, Warmolts J, Mendell J. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 1989;46:878-884.
15. Barwick D, Walton J. Polymyositis. Am J Med 1963;35:646-659.
16. Begg E, Atkinson H, Gianarakis N. The pharmacokinetics of corticosteroid agents. Med J Austral 1987;146:37-41.
17. Biggar W, Gingras M, Fehlings D, Harris V, Steele C. Deflazacort treatment of Duchenne muscular dystroophy. J Pediatr 2001;138:45-50.
18. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-720.
19. Blood A, Locke W, Carabasi R. Guillain-Barré syndrome treated with corticotropin (ACTH). JAMA 1953;152:139-140.
20. Bohan A, Peter J. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-347.
21. Bonifati M, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-1347.
22. Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972;13:694-698.
23. Boumpas D. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119:1198-1208.
24. Braithwaite S, Barr W, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. Postgrad Med 1998;104:163-178.
25. Brooke M, Fenichel G, Griggs R, Mendell J, Moxley R, Miller J, Province M, Group. C. Clinical investigation in Duchenne dystrophy: 2. Determination of the 'power' of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
26. Brooke M, Fenichel G, Griggs R, Mendell J, Moxley R, Miller J, Kaiser K, Florence J, Pandya S, Signore L, King W, Robison J, Head R, Province M, Seyfried W, Mandel S. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol 1987;44:812-817.
27. Bunim J, Pechet M, Bollet A. Studies on metacortandralone and metacortandracin in rheumatoid arthritis. JAMA 1955;157:311-318.
28. Campbell H, Bramwell E. Myasthenia gravis. Brain 1900;23:277-336.
29. Carson J, Strom B, Schinnar R, Duff A, Sim E. The low risk of upper gastrointestinal bleeding in patients dispensed corticosteroids. Am J Med 1991;91:223-228.
30. Chau S, Mok C. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003;61:104-107.
31. Christianson H, Brunsting L. Dermatomyositis: unusual features, complications, and treatment. Arch Dermatol 1956;74:581-589.
32. Christy N. The clinical significance of pituitary-adrenal suppression by exogenous corticosteroids. J Chron Dis 1973;26:261-263.
33. Conn H, Blitzer B. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976;294:473-479.
34. Conn H, Poynard T. Adrenocorticosteroid administration and peptic ulcer: a critical analysis. J Chron Dis 1985;38:457-468.
35. Connolly A, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002;12:917-920.
36. Curtis J, Galla J, Woodford W, Saykaly R, Luke R. Comparison of daily and alternate-day prednisone during chronic maintenance therapy: a controlled crossover study. Am J Kidney Dis 1981;1:166-171.
37. Dalakas M, Engel W. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981;9(Suppl):134-145.
38. Dalakas M. Treatment of polymyositis and dermatomyositis with corticosteroids: a first therapeutic approach. In: Dalakas M, editor. Polymyositis and dermatomyositis. Boston: Butterworths; 1988. p 235-253.
39. Dale D, Petersdorf R. Corticosteroids and infectious diseases. Med Clin N Am 1973;57:1277-1287.
40. Delcourt C, Cristol J-P, Léger C, Michel F, Papoz L. Risk factors of cortical, nuclear, and posterior subcapsular cataracts. Am J Epidemiol 2000;151:497-504.
41. DeSilva S, Drachman D, Mellits D, Kuncl R. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 1987;44:818-822.
42. DeVere R, Bradley W. Polymyositis: its presentation, morbidity and mortality. Brain 1975;98:637-666.
43. DeVivo D, Engel W. Remarkable recovery of a steroid-responsive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry 1970;33:62-69.
44. Dixon R, Christy N. On the various forms of corticosteroid withdrawal syndrome. Am J Med 1980;68:224-230.
45. Drachman D, Toyka K, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1974;2:1409-1412.
46. Drachman D, Toyka K, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 1975;1:397-398.
47. Dropcho E, Soong S. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235-1239.
48. Dyck P, Lais A, Ohta M, Bastron J, Okazaki H, Groover R. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-636.
49. Dyck P, O'Brien P, Oviatt K, Dinapoli R, Daube J, Bartleson J, Mokri B, Swift T, Low P, Windebank A. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
50. Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med 1995;237:439-447.
51. Eaton L. The perspective of neurology in regard to polymyositis. Neurology 1954;4:245-263.
52. Edgeworth H. A report of progress on the use of ephedrine in a case of myasthenia gravis. JAMA 1930;94:1136.
53. Elkinton J, Hunt A, Godfrey, McCorory W, Rogerson A, Stokes J. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy. JAMA 1949;141:1273-1279.
54. English J, Dunne M, Marks V. Diurnal variation in prednisolone kinetics. Clin Pharmacol Ther 1983;33:381-385.
55. Evoli A, Batocchi A, Palmisani M, Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992;32:37-43.
56. Fauci A, Dale D, Balow J. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304-315.
57. Fauci A. Alternate-day corticosteroid therapy. Am J Med 1978;64:729-731.
58. Fenichel G, Florence J, Pestronk A, Mendell J, Moxley R, Griggs R, Brooke M, Miller J, Robinson L, King W, Signore L, Pandya S, Schierbecker J, Wilson A. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991;41:1874-1877.
59. Fordyce M, Solomon L. Early detection of avascular necrosis of the femoral head by MRI. J Bone Joint Surg [Br] 1993;75-B:365-367.
60. Frey B, Frey F. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-146.
61. Frey F, Lozada F, Guentert T, Frey B. A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 1981;19:209-212.
62. Frey F, Rüegsegger M, Frey B. The dose-dependent systematic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone. Br J Clin Pharmacol 1986;21:183-189.
63. Frey F, Schnetzer A, Horber F, Frey B. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987;43:494-498.
64. Frey F, Horber F, Frey B. Altered metabolism and decreased efficacy of prenisolone and prednisone in patients with hyperthyroidism. Clin Pharmacol Ther 1988;44:510-521.
65. Frev J. Kinetics and dynamics of prednisolone. Endocrine Rev 1987;8:453-473.
66. Gambertoglio J, Amend W, Benet L. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharmacodyn 1980;8:1-52.
67. Genkins G. Myasthenia gravis. Ann NY Acad Sci 1966;135:348-349.
68. Gluck O, Murphy W, Hahn T, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981;24:892-898.
69. Griggs R, McFarlin D, Engel W. Severe occult juvenile myasthenia gravis responsive to long-term corticosteroid therapy. Trans Am Neurol Assoc 1968;93:216-218.
70. Griggs R, Nash R. Diphasic response to corticosteroids in idiopathic relapsing polyneuropathy. Arch Neurol 1976;33:794-795.
71. Griggs R, Moxley R, Mendell J, Fenichel G, Brooke M, Pestronk A. Duchenne Dystrophy Group. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Arch Neurol 1991;48:383-388.
72. Grob D, Harvey M. Effects of adrencorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. JAMA 1966;198:703-707.
73. Gunvitz J, Bohn R, Glynn R, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk of initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.
74. Harter J, Reddy W, Thorn G. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963;269:591-596.
75. Hench P, Kendall E, Slocumb C, Polley H. The effects of a hormone of the adrenal cortex (17-hydroxy-11-dehydocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 1949;24:181-197.
76. Hench P, Kendall E, Slocumb C, Polley H. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med 1950;85:545-666.
77. Hendriksson K, Sandstedt P. Polymyositis-treatment and prognosis. Acta Neurol Scand 1982;65:280-300.
78. Hinman R, Magee K. Guillain-Barré syndrome with slow progressive onset and persistent elevation of spinal fluid protein. Ann Intern Med 1967;67:1007-1012.
79. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Engeland T, Fauchald P. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-983.
80. Hoogwerf B, Danese R. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin N Am 1999;25:489-505.
81. Horber F, Scheidegger J, Grünig B, Frey F. Evidence that prednisone-induced myopathy in reversed by physical training. J Clin Endocrinol Metab 1985;61:83-88.
82. Jackson R, Miller H, Schapira K. Polyradiculitis (Landry-Guillain- Barŕ syndrome): treatment with cortisone and corticotropin. BMJ 1957;1:480-484.
83. Jenkins J, Sampson P. Conversion of cortisone to cortisol and prednisone to prednisolone. BMJ 1967;2:205-207.
84. Jenkins R. Treatment of myasthenia gravis with prednisone. Lancet 1972;1:765-767.
85. Kimball C. Psychological dependency on steroids. Ann Intern Med 1971;75:111-113.
86. Kjaer M. Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol Scand 1971;47:464-474.
87. Kozower M, Veatch L, Kaplan M. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. J Clin Endocrinol Metab 1974;38:407-412.
88. Leger U, Benet L. Marked alterations in prednisolone elimination for women taking oral contraceptives. Clin Pharmacol Ther 1982;31:243.
89. Leske M, Chylack L, Wu S-Y. The lens opacities case-control study. Risk factors for cataract. Arch Ophthalmol 1991;109:244-251.
90. Lewis G, Jusko W, Burke C, Graves L. Prednisone side-effects and serum-protein levels. Lancet 1971;2:778-780.
91. Lindberg C, Andersen O, Lefvert A. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998;97:370-373.
92. Logan R, Bandera J, Mikkelsen W, Duff I. Polymyositis: a clinical study. Ann Intern Med 1966;65:996-1007.
93. Lopez-Medrano F, Cervera R, Trejo O, Font J, Ingelmo M. Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin level. Ann Rheum Dis 2002;61:562-563.
94. Mankin H. Nontraumatic necrosis of bone (osteonecroses). N Engl J Med 1992;326:1473-1479.
95. Mann J, Johns T, Campa J. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976;26:729-740.
96. Markham A, Brysonl H. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 1995;50:317-333.
97. Marsh DO. Adrenal therapy for neuromuscular disease including myasthenia gravis from 1896. NY State J Med 1974;74:1974-1976.
98. Matthews W, Howell D, Hughes R. Relapsing corticosteroid-dependent polyneuritis. J Neurol Neurosurg Psychiatry 1970;33:330-337.
99. McElligott M. Corticotropin and cortisone therapy in dermatomyositis. BMJ 1956:1509-1511.
100. McQuillen M. Prednisone schedule for myasthenia gravis. N Engl J Med 1974;290:631.
101. Meffin P, Brooks P, Sallustio B. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 1984;17:394-404.
102. Mehndiratta M, Hughes R. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane review). Cochrane Database Syst Rev 2002 (update software).
103. Meikle A, Weed J, Tyler F. Kinetics and interconversion of prednisolone and rednisone studied with new radioimmunoassays. J Clin Endocrinol Metab 1975;41:717-721.
104. Mendell J, Moxley R, Griggs R, Brooke M, Fenichel G, Miller J, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robinson L, Kaiser K, Mandel S, Arfken C, Gilder B. Randomized, double-blind six-month trial of prednisone in Duchenne muscular dystrophy. N Engl J Med 1989;320:1592-1597.
105. Mesa L, Dubrovsky A, Marco J, Flores D. Steroids in Duchenne muscular dystrophy-Deflazacort trial. Neurobiol Dis 1991;1:261-266.
106. Messer J, Reitman D, Sacks H, Smith H, Chalmers T. Association of adrenocorticoid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-24.
107. Metselaar H, van Steenberge E, Bijnen A, Jeekel J, van Linge G, Weimar W. Incidence of osteonecrosis after renal transplantation. Acta Orthop Scand 1985;56:413-415.
108. Miller R, Milner-Brown H, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986;36:729-732.
109. Miller S, Neilson J. Clinical features of the diabetic syndrome appearing after steroid therapy. Postgrad Med J 1964;40:660-669.
110. Millikan C, Eaton L. Clinical evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1951;1:145-152.
111. Milsap R, Plaisance K, Jusko W. Prednisolone disposition in obese men. Clin Pharmacol Ther 1984;36:824-831.
112. Mirzai R, Chang C, Greenspan A, Gershwin M. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 1999;36:77-95.
113. Moehlig R. Myasthenia gravis: treatment by implantation of desoxycorticosterone acetate pellets. JAMA 1940;115:123-125.
114. Molenaar D, van Doorn P, Vermeulen M. Pulse high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. Neurol Neurosurg Psychiatry 1997;62:388-390.
115. Mulder D, Winkelmann R, Lambert E, Diessner G, Howard F. Steroid therapy in patients with polymyositis and dermatomyositis. Ann Intern Med 1963;58:969-976.
116. Munsat T, Walton J. Prednisone in Duchenne muscular dystrophy. Lancet 1975;1:276-277.
117. Newey J, Lubin R. Corticotropin (ACTH) therapy in Guillain-Barré syndrome. JAMA 1953;152:137-139.
118. O'Leaur P, Waisman M. Dermatomyositis. Arch Dermatol Syphilol 1940;41:1001-1019.
119. Olbricht T, Benker G. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases. J Int Med 1993;234:237-244.
120. Olsson R, Lindberg C, Andersen O. Centrolobular liver-cell necrosis, myocardial infarction and hyperamylasaemia after high dose corticosteroids. BMJ 1994;308:454.
121. Oppel T, Coker C, Milhorat A. The effect of pituitary adrenocorticotropin (ACTH) in dermatomyositis. Ann Intern Med 1950;32:318-324.
122. Osserman K, Genkins G. Studies in myasthenia gravis: short-term corticotropin therapy. JAMA 1966;198:669-702.
123. Palace J, Newsom-Davis J, Lecky B, Group MGS. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
124. Pascuzzi R, Coslett B, Johns T. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
125. Patten S, Neutel C. Corticosteroid-induced adverse psychiatric effects. Incidence, diagnosis and management. Drug Safety 2000;22:111-122.
126. Pearson C. Polymyositis: clinical forms, diagnosis and therapy. Postgrad Med 1962;31:450-458.
127. Pearson C. Patterns of polymyositis and their response to treatment. Ann Intern Med 1963;59:827-838.
128. Perkoff G, Silber R, Tyler F, Cartwright G, Wintrobe M. Studies in disorders of muscle. XII. Myopathy due to administration of therapeutic amounts of 17-hydroxycorticosteroids. Am J Med 1959;26:891-898.
129. Pickup M. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1979;4:111-128.
130. Pinelli P, Tonali P, Scoppetta C. Long-term treatment of myasthenia gravis with alternate-day prednisone. Eur Neurol 1974;12:129-141.
131. Piper J, Ray W, Daugherty J, Griffin M. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-740.
132. Pleasure D, Walsh G, Engel W. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 1970;22:118-125.
133. Plum F. Multiple symmetrical polyneuropathy treated with cortisone. Neurology 1953;3:661-667.
134. Polley H, Mason H. Rheumatoid arthritis. JAMA 1950;143:1474-1481.
135. Polley H. Present therapeutic status of cortisone and its derivatives, with special reference to rheumatic diseases. BMJ 1956;2:1253-1259.
136. Polley H. Evolution of steroids and their value in the control of rheumatic disease. Mayo Clin Proc 1970;45:1-12.
137. Prineas J, McLeod J. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
138. Reichling G, Kligman A. Alternate-day corticosteroid therapy. Arch Dermatol 1961;83:134-137.
139. Reid J. Therapy of osteoporosis: calcium, vitamin D, and exercise. Am J Med Sci 1996;312:278-286.
140. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995;17(Suppl):39-43.
141. Renner E, Horber F, Jost G, Frey B, Frey F. Effects of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 1986;90:819-828.
142. Richards J, Santiago S, Klaustermeyer W. Aseptic necrosis of the femoral head in corticosteroid-treated pulmonary disease. Arch Intern Med 1980;140:1473-1475.
143. Riddoch D, Morgan-Huges J. Prognosis in adult polymyositis. J Neurol Sci 1975;26:71-80.
144. Rose A, Walton J. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain 1966;89:747-768.
145. Rowland L. Prednisone in Duchenne muscular dystrophy. Lancet 1975;1:397-398.
146. Saag K, Emkey R, Schnitzer T, Brown J, Hawkins F, Goemaere S, Thamsborg G, Liberman U, Delmas P, Malice M-P, Czachur M, Daifontis A, Glucocorticoid-induced Osteoporosis Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299.
147. Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis in positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976;84:261-265.
148. Schlaghecke R, Kornely E, Santen R, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992;326:226-230.
149. Schlezinger N. Present status of therapy in myasthenia gravis. JAMA 1952;148:508-513.
150. Schürmeyer T, Tsokos G, Avgerinos P, Balow J, D'Agata R, Loriaux D, Chrousos G. Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy. J Clin Endrocrinol Metab 1985;61:22-27.
151. Seale P, Compton M. Side-effects of corticosteroid agents. Med J Austral 1986;144:139-142.
152. Seybold M, Drachman D. Gradually increasing doses of prednisone in myasthenia gravis. N Engl J Med 1974;290:81-84.
153. Sheard C. Dermatomyositis. Arch Intern Med 1951;88:640-658.
154. Shy G, Rabinovitch R, McEachern D. Effects of cortisone in certain neuromuscular disorders. JAMA 1950;144:1353-1358.
155. Siegel I, Miller J, Ray R. Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study. III Med J 1974;145:32-36.
156. Simmons Z, Albers J, Bromberg M, Feldman E. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-2209.
157. Simmons Z, Albers J, Bromberg M, Feldman E. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-368.
158. Simon H. Myasthenia gravis effect of treatment with anterior pituitary extract: preliminary report. JAMA 1935;104:2065-2066.
159. Smith A, Bromberg M. Treatment of inflammatory demyelinating neuropathies. J Clin Neuromuscul Dis 1999;1:21-31.
160. Stillman J, Ganong W. The Guillain-Barré syndrome: report of a case treated with ACH and cortisone. N Engl J Med 1952;246:293-296.
161. Stuck A, Frey B, Frey F. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther 1988;43:354-362.
162. Stuck A, Minder C, Frey F. Risk of infections complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-963.
163. Sullivan T, Hallmark M, Sakmar E, Weidler D, Earhart R, Wagner J. Comparative bioavailability: eight commercial prednisone tablets. J Pharmacokinet Biopharmacodyn 1976;4:157-172.
164. Tanner A, Carrin J, Halliday J, Powell L. Concurrent administration of antacids and prednisone: effects on serum levels of prednisolone. Br J Clin Pharmacol 1979;7:397-400.
165. Tervonen O, Mueller D, Matteson E, Velosa J, Ginsburg W, Ehman R. Clinically occult avascular necrosis of the hip: prevalence in an asymptomatic population at risk. Radiology 1992;182:845-847.
166. Torda C, Wolff H. Effects of adrenotrophic hormone of pituitary gland on ability of tissue to synthesize acetylcholine. Proc Soc Exp Biol Med 1944;57:137-139.
167. Torda C, Wolff H. Effects of adrenocorticotrophic hormone on neuro-muscular function in patients with myasthenia gravis. Proc Soc Exp Biol Med 1949;71:432-435.
168. Torda C, Wolff H. Effects of administration of the adrenocorticotropic hormone (ACTH) on patients with myasthenia gravis. Arch Neurol Psychiatry 1951;66:163-170.
169. Tripathi R, Parapuram S, Tripathi B, Zhong Y, Chalam K. Corticosteroids and glaucoma risk. Drugs Aging 1999;15:439-450.
170. Tsang S, Garovoy M, Benet L. Immunosuppressive activity of prednisone and prednisolone and their metabolic interconversion in the mixed lymphocyte reaction. Int J Immunopharmacol 1985;7:731-737.
171. Uchino M, Araki S, Yoshida O, Uekawa K, Nagata J. High single-dose alternate-day corticosteroid regimens in treatment of polymyositis. J Neurol 1985;232:175-178.
172. Vesco L, Busson M, Bedrossian J, Bitker O, Hiesse C, Lang P. Diabetes mellitus after renal transplantation. Transplantation 1996;61:1475-1478.
173. Walker M. Treatment of myasthenia gravis with physostigmine. Lancet 1934;226:1200-1201.
174. Warmolts J, Engel W, Whitaker J. Alternate-day prednisone in a patient with myasthenia gravis. Lancet 1970;2:1198-1199.
175. Warmolts J, Engel W. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20.
176. Wedgwood R, Cook C, Cohen J. Dermatomyositis. Pediatrics 1953;12:447-466.
177. Weiner H, Rezai A, Cooper P. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. Neurosurgery 1993;33:40-43.
178. Wertman E, Argov Z, Abramasky O. Chronic inflammatory demyelinating polyradiculoneuropathy: features and prognostic factors with corticosteroid therapy. Eur Neurol 1988;28:199-204.
179. Zizic T, Marcoux C, Hungerford D, Dansereau J-V, Stevens M. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985;79:596-603.